Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02939989 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

A Phase 3 study of Hepatitis C Virus Infection, sponsored by AbbVie.

Completed
Registry status
Phase 3
Development phase
33
Enrollment target
20
Study locations

NCT02939989 is a Phase 3 study of Hepatitis C Virus Infection that has completed, run by AbbVie. The registered enrollment target is 33 participants, below the 196-participant average among 5 other Hepatitis C Virus Infection trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02939989, a Phase 3 study of Hepatitis C Virus Infection, has completed, sponsored by AbbVie.

COMPLETED
Registry status
Phase 3
Development phase
33 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study was to evaluate the efficacy and safety of co-administration of glecaprevir (ABT-493)/pibrentasvir (ABT 530) plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 - 6-infected participants (including non-cirrhotic, or cirrhotic with compensated cirrhosis participants) who had experienced virologic failure in an AbbVie parent clinical study.

Conditions Studied

Hepatitis C Virus Infection

Interventions

  • DRUG Ribavirin
  • DRUG Sofosbuvir
  • DRUG Glecaprevir/Pibrentasvir

Study Locations (20)

Other

  • Beijing Di Tan Hospital, Capital Medical University /ID# 218496 - Beijing
  • West China Hospital, Sichuan University /ID# 217613 - Chengdu
  • The First Hospital Affiliated to AMU (Southwest Hospital) /ID# 218494 - Chongqing
  • Mengchao Hepatobiliary Hospital of Fujian Medical University /ID# 218495 - Fuzhou
  • Asklepios Klinik St. Georg /ID# 155733 - Hamburg

Alabama

  • Digestive Health Specialists of the Southeast /ID# 155719 - Dothan

California

  • Ruane Clinical Research Group /ID# 155714 - Los Angeles

Maryland

  • Digestive Disease Associates - Baltimore /ID# 155713 - Baltimore

Michigan

  • Henry Ford Health System /ID# 155720 - Detroit

New York

  • University of Buffalo /ID# 155721 - Buffalo

North Carolina

  • Carolinas Center For Liver Dis /ID# 155731 - Statesville

Tennessee

  • Gastro One /ID# 155729 - Germantown

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2016-11-21
Est. Completion 2021-07-30
Phase Phase 3

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02939989

The ClinicalTrials.gov registry entry for NCT02939989 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 196-participant average among 5 other Hepatitis C Virus Infection trials with a reported enrollment target (83% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatitis C Virus Infection appearing as the primary indexed condition, and to 3 interventions - of which Ribavirin is the first listed.

NCT02939989 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT02939989 about?

NCT02939989 is a clinical study titled "Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study". The purpose of this study was to evaluate the efficacy and safety of co-administration of glecaprevir (ABT-493)/pibrentasvir (ABT 530) plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 - 6-infected participants (including non-cirrhotic, or cirrhotic with compensat...

What is the current status of trial NCT02939989?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 33 participants. The study started on 2016-11-21. Estimated completion is 2021-07-30.

What conditions does trial NCT02939989 study?

This clinical trial studies the following conditions: Hepatitis C Virus Infection.

What interventions are being tested in trial NCT02939989?

The interventions under investigation include: Ribavirin (DRUG), Sofosbuvir (DRUG), Glecaprevir/Pibrentasvir (DRUG).

Who is sponsoring clinical trial NCT02939989?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02939989 being conducted?

This trial has 20 study locations across Alabama, California, Maryland, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C Virus Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatitis C Virus Infection

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.